microRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by targeting messenger RNA (mRNA) transcripts. Recently, a miRNA expression profile of human tumors has been characterized by an overall miRNA downregulation [1] [2] [3] . Explanations for this observation include a failure of miRNA post-transcriptional regulation 4 , transcriptional silencing associated with hypermethylation of CpG island promoters [5] [6] [7] and miRNA transcriptional repression by oncogenic factors 8 . Another possibility is that the enzymes and cofactors involved in miRNA processing pathways may themselves be targets of genetic disruption, further enhancing cellular transformation 9 . However, no loss-of-function genetic alterations in the genes encoding these proteins have been reported. Here we have identified truncating mutations in TARBP2 (TAR RNA-binding protein 2), encoding an integral component of a DICER1-containing complex 10, 11 , in sporadic and hereditary carcinomas with microsatellite instability [12] [13] [14] . The presence of TARBP2 frameshift mutations causes diminished TRBP protein expression and a defect in the processing of miRNAs. The reintroduction of TRBP in the deficient cells restores the efficient production of miRNAs and inhibits tumor growth. Most important, the TRBP impairment is associated with a destabilization of the DICER1 protein. These results provide, for a subset of human tumors, an explanation for the observed defects in the expression of mature miRNAs.
In order to explore the presence of inactivating mutations in the socalled 'miRNA processing machinery genes' it is useful to consider tumors that show microsatellite instability, both in the context of hereditary nonpolyposis colon cancer (HNPCC) associated with germline mutations in the mismatch repair genes 14 and in sporadic cancers associated with hMLH1 inactivation by promoter CpG island methylation 12, 13 . Tumors with microsatellite instability progress along a genetic pathway with a high rate of insertion and deletion mutations in mononucleotide repeats, which often results in the generation of premature stop codons. Illustrative target genes include the growthcontrol gene TGFBR2 (ref. 15 ) and the proapoptotic gene BAX 16 .
We first screened six colorectal (Co115, RKO, SW48, LoVo, HCT-15 and HCT-116), four endometrial (SKUT-1, SKUT-1B, AN3CA and HEC1B) and two gastric (SNU-1 and SNU-638) cancer cell lines with microsatellite instability for the presence of mutations in all the exonic mononucleotide repeats present in the coding sequences of eight established members of the miRNA processing machinery: the RNase III family of double-stranded RNases (DICER1 and DROSHA), RNA-binding proteins that act as catalytic partners (DGCR8, TRBP and PACT) and Argonaute members (AGO1, AGO2 and AGO4). The location of the corresponding repeats and the PCR primers used are shown in the Supplementary Table 1 online. We detected only wildtype sequences for all the genes described, with the single notable exception of TARBP2 (Fig. 1a) . We found two frameshift mutations in TARBP2: the deletion of a C in a (C) 5 coding microsatellite repeat of exon 5 in the colorectal cancer cell line Co115 and the insertion of a C in a (C) 7 coding microsatellite repeat of exon 5 in the endometrial cancer cell line SKUT-1B (Fig. 1a) . The TARBP2 mutations were present in 29 of 41 (71%) and 17 of 31 (55%) single-clone sequences obtained from genomic DNA for Co115 and SKUT-1B, respectively. The same proportion of mutant alleles was found when we used cDNA as starting material; thus, these are heterozygous mutations. The two alleles of TARBP2 were retained in both cell lines according to the FISH analysis ( Supplementary Fig. 1 online) . We analyzed TRBP protein expression in Co115 and SKUT-1B cell lines and found very low and diminished expression, respectively (Fig. 1b) . We did not observe any evidence of TARBP2 mutations in colorectal (SW480, SW620 and COLO205) and endometrial (KLE) cancer cell lines that lacked microsatellite instability.
Once the presence of inactivating mutations of TARBP2 in cancer cells had been confirmed, it became very important to establish whether they affect the processing efficiency of pre-miRNAs. We first assessed the processing efficiency of pre-miRNAs in TARBP2 mutant colorectal cancer cells (Co115) in comparison with TARBP2 wild-type colorectal cancer cells (RKO and HCT116) 17 . We found that TRBP-deficient cells featured a mean 90% reduction in the efficiency of endogenous processing miRNAs relative to TRBP-proficient cells (Fig. 1c) . To strengthen the evidence of a link between TARBP2 mutations and the impaired miRNA phenotype observed, we reconstituted TRBP function in TRBP-deficient cancer cells (Co115) (Fig. 2 and Supplementary Fig. 1 ). Transfection of wild-type TARBP2 in Co115 cells (Fig. 2a) restored the pre-miRNA processing capacity for both the endogenous pre-miRNAs (Fig. 2b,c) and for the synthetic precursor molecules that we had introduced (Fig. 2d) . Pri-miRNA concentrations did not change upon TARBP2 transfection (Supplementary Fig. 1) . Transfection of the mutant form of TARBP2 (C deletion of the (C) 5 coding repeat in exon 5) in Co115 cells (Fig. 2a) was unable to restore pre-miRNA processing capacity (Fig. 2b,d) . We then used a microarray platform 18 to study the global miRNA expression profile of Co115 cells upon transfection of wild-type TARBP2. We Figure 2 Transfection of wild-type TARBP2 rescues pre-miRNA processing capacity. (a) TRBP protein expression was restored after transfecting wild-type TARBP2 in Co115 cell line. Stable clones were selected treating cells with puromycin (left). As a control, the truncated form of TARBP2, due to the mutation in the (C) 5 repeat, was also transfected in a pCMV-Tag4b vector and tested using an antibody against Flag. Stable clones were selected using G418. pre-let7 pre-miR-125b miR-125b miR-let7 miR-22 Fig. 1 ). TRBP is an integral component of a DICER1-containing complex 10, 11 ; it interacts directly with the DICER1 protein 10, 11 and is required for the stabilization of the DICER1 protein 10 . This prompted us to consider how the presence of TARBP2-inactivating mutations affect DICER1 activity. When we analyzed the expression of the DICER1 protein in TARBP2 wild-type colorectal cancer cell lines and the TARBP2 mutant Co115 cells, this latter cell line was the only one in which DICER1 protein expression was extremely low (Fig. 3a) . For the endometrial cancer cell lines, mutant TARBP2 SKUT-1B cells also presented diminished DICER1 protein concentrations compared to wild-type SKUT-1 cells (Fig. 3a) . We did not observe DICER1 mutation, promoter CpG island methylation, genomic loss or increased ubiquitin-protein degradation ( Supplementary Fig. 4 online). When we reconstituted TRBP expression in Co115 cells by transfection of a wild-type TARBP2 construct, the protein expression of DICER1 was restored (Fig. 3b) . The transfected mutant form of TARBP2 was unable to rescue DICER1 protein expression (Fig. 3b) . Protein translation inhibition by cycloheximide in Co115 cells was unable to show DICER1 stabilization, but it was observed upon TARBP2 transfection, as it also occurred in wild-type TARBP2 cancer cells ( Supplementary  Fig. 4 ). These results are evidence that the loss of TRBP results in the destabilization of the DICER1 protein 10 and underpin the absence of a functional DICER1-TRBP complex in Co115 cells.
Having demonstrated that the TARBP2 mutant cells also had a secondary associated defect in DICER1, we reconstituted DICER1 activity (Fig. 3c) . The Co115 DICER1-transfected cells were not able to restore TRBP protein concentrations because the TARBP2 mutation was present (Fig. 3c) ; however, they relatively increased the efficacy of miRNA processing in the endogenous pre-miRNAs (Fig. 3d) and in those introduced exogenously (Fig. 3e) . The cotransfection of TARBP2 and DICER1 in Co115 TARBP2 mutant cells caused a slightly higher miRNA processing fold than for each single gene ( Supplementary  Fig. 5 online) . In contrast, the downregulation of DICER1 by RNA interference in cells with wild-type TARBP2 (RKO) was associated with impaired pre-miRNA processing ( Supplementary Fig. 6 online) .
Most notably from the tumor biology standpoint, the ectopic expression of TRBP in the deficient cells induced tumor suppressorlike features (Fig. 4) . Upon restoration of TRBP expression in Co115 TRBP-deficient colorectal cancer cells, the cells proved less viable in the MTT assay (Fig. 4a) and markedly reduced percentage colony formation density (Fig. 4b) . Transfection of the mutant form of TARBP2 in Co115 cells was unable to reduce cell viability (Fig. 4a) and had no impact on the colony formation assay (Fig. 4b) . Overexpression of TRBP in the wild-type TARBP2 colorectal cancer cell line RKO was unable to reduce cell viability ( Supplementary Fig. 6 ). We next tested the ability of TARBP2-transfected Co115 cells to form tumors in nude mice (Fig. 4c) . Co115 TRBP-deficient cells transfected with the empty vector or the mutant gene formed tumors rapidly, but cells transfected with the wild-type TARBP2 had much lower tumorigenicity (Fig. 4c) . In contrast, the downregulation of TARBP2 by short hairpin RNA in cells with wild-type TARBP2 (RKO and HCT-116) was associated with increased viability and clonogenicity ( Supplementary Fig. 6) .
Notably, the reintroduction of DICER1 in Co115 TARBP2 mutant cells also showed tumor-suppressor properties: the cells were less viable in the MTT assay (Fig. 4d) , they had a lower percentage colony formation density (Fig. 4e) and their ability to form tumors in nude mice was lower (Fig. 4f) . The cotransfection of TARBP2 and DICER1 together inhibited colony formation and the development of tumors in mice to a slightly greater extent ( Supplementary Fig. 5 ). These data showing how both the loss of TARBP2 and/or DICER1 compromises precursor miRNA processing and the potential tumor-suppressor features of both genes are consistent with the recently described enhancement of cellular transformation and tumorigenesis upon depletion of DICER1 in human cells 9 and in a conditional deletion of DICER1 in a mice model 9 . Most important, reduced DICER1 expression has been observed in lung tumors associated with poor prognosis 23 . Thus, our data underline the proposed role of different components of the miRNA processing machinery, and a subgroup of miRNAs, as tumor suppressor genes 19 . Finally, we sought to measure the frequency of the described TARBP2 disruption in human primary tumors. We assessed the TARBP2 mutational status of 282 human primary malignancies with microsatellite instability, including colorectal tumors from individuals with HNPCC (n ¼ 30) and sporadic colorectal (n ¼ 209) and gastric (n ¼ 43) malignancies ( Table 1) . We found that TARBP2 frameshift mutations were present in 26% (72 of 282) of the primary tumors analyzed. The deletion of a C in the (C) 5 coding microsatellite repeat of exon 5 was noted in 63 cases and there was an insertion of a C in a (C) 7 coding microsatellite repeat of exon 5 in the remaining nine cases. No single tumor featured both mutations, which highlights the functional relevance of each mutational event. The presence of TARBP2 wild-type sequences suggested that the mutations were heterozygous. The described TARBP2 mutations were not present in primary colorectal tumors without microsatellite instability (0/50), normal colorectal mucosa (0/50) or in normal lymphocytes from healthy donors (0/80) ( Table 1) . TARBP2 mutations were also absent in lymphocytes from individuals with HNPCC (0/12), in whom the corresponding colon tumors had TARBP2 mutations ( Table 1) . For 20 cases of microdissected primary sporadic colon tumors with microsatellite instability, and 10 corresponding normal colorectal mucosa, we conducted a TRBP protein blot expression analysis (Supplementary Fig. 7 online) . In all cases with wild-type TARBP2, 10 primary tumors and all normal mucosa samples, TRBP protein was strongly expressed. In contrast, the 10 TARBP2 mutant tumors demonstrated diminished expression of the TRBP protein ( Supplementary Fig. 7) .
In summary, we have demonstrated the presence of inactivating mutations in the gene encoding the RNA-binding protein TRBP, an essential functional partner of DICER1, in human cancer cell lines and primary tumors with microsatellite instability that impairs miRNA processing and enhances cellular transformation. The loss of TRBP also leads to a secondary defect in DICER1 activity. These findings are evidence of the role of loss of function events in the regulation of miRNA processing machinery during tumorigenesis. Because the restoration of efficient miRNA production can block cancer cell growth, these findings are potentially relevant to the development of new therapeutic strategies for the treatment of cancer. Mutation analysis. Genomic DNA from cell lines and primary tumors and cDNA from the cell lines were amplified by PCR. PCR products and recombinant plasmids from single clones of every sample were sequenced in an automated ABI Prism 3700 sequencer. The genes studied, their genomic locations and the primers used are described in Supplementary Table 1. FISH analysis. FISH was done by standard methods. We used the UCSC genome browser to select for the TARBP2 gene the two BAC clones spanning the 12q13 region: RP11-793H13 and RP11-101H10, and for DICER1 gene the BAC clone covering the 14q32 region: RP11-1143O10. The BACs were obtained from the Children's Hospital Oakland Research Institute in Oakland, USA. We used commercial centromeric probes for chromosomes 12 and 14 (Vysis) as control.
METHODS
Analysis of TARBP2 and DICER1 CpG island promoter methylation. DNA samples were treated with sodium bisulfite and primers spanning the CpG island of the TARBP2 and DICER1 promoters were used for bisulfite genomic sequencing. Primer sequences and PCR conditions are available upon request. We analyzed ten clones per sample.
Protein blotting. For protein blotting of TRBP and DICER1 expression, total protein extracts were immunoprobed with antibodies to TRBP (monoclonal ABNOVA 1:1,000) and DICER1 (1:500, Santa Cruz H212). We used an antibody against b-actin (1:5000; Sigma, St. Louis, MO) or nucleolin (1:1000; Santa Cruz) as a loading control.
RNA isolation. Total RNA was isolated by Trizol (Invitrogen). Extraction was carried out according to the manufacturer's instructions.
Quantification of miRNAs with real-time PCR. We used TaqMan MiRNA assays to quantify mature miRNAs as described previously 24 . Each reverse transcriptase (RT) reaction contained 10 ng of purified and DNase-treated (Turbo DNA-free, Ambion) total RNA, 50 nM stem-loop RT primer, 1 Â RT buffer, dNTPs (each at 1 mM), 16. 17 to determine relative quantitative levels of individual miRNAs, using GADPH for normalization, and expressed values as the relative difference compared to the relevant controls. The primers used are described online in Supplementary Table 1 .
Precursor miRNA qPCR. SuperScript III Platinum One-Step RT-qPCR kit (Invitrogen) was used to quantify precursor miRNAs by RT-qPCR 25 .
The precursor miRNAs to be tested were selected according to the colorectal miRNAome identified by Cummins et al. 26 . The primers used are described online in Supplementary Table 1. miRNA processing efficiency. The changes in miRNA processing efficiency were plotted as 'relative processing' and 'processing fold' . Relative processing was defined as the ratio of mature to precursor miRNA. Processing fold was defined as the ratio of mature to precursor miRNA in transfected cells divided by the ratio of mature to precursor miRNA in empty vector transfected cells 4 .
Processing fold ¼ 2
ÀðDCt:miR=DCt:PreÀmiRÞTransfected 2 ÀðDCt:miR=DCt:PreÀmiRÞEmptyVector
Total RNA was extracted from three independent experiments and the results presented are the means of these.
Northern blot. Forty micrograms of total RNA together with Decade Marker (Ambion) were resolved in 15% denaturating polyacrylamide gel containing 7 M urea in 0.5XTBE buffer system and transferred onto Hybond-N+ membrane (Amersham) in 0.5XTBE. Probes were radioactively labeled with 25 mCie [g-32P] ATP (PerkinElmer) and T4 kinase (Invitrogen), and purified with Nucaway Spin columns (Ambion). Membranes were UV-cross linked (1200 jules), prehybridized in hybridization buffer and hybridized overnight in the same solution at 37 1C containing the radioactively labeled probed previously heated at 95 1C for 2 min. Membranes were washed at low stringency followed by film exposure. Probes used are described online in Supplementary Table 1. RNA interference. TARBP2-and DICER1-specific small interfering RNAs (siRNA) were designed and synthesized by Qiagen. Two siRNA duplexes that recognized two different sequences were used against the TARBP2 gene, and likewise for the DICER1 gene. TARBP2 and DICER1 expression was analyzed by qRT-PCR and protein blotting; pre-miRNA and miRNAs were assessed by qRT-PCR, as described above.
Transfections of TARBP2 and DICER1. The wild-type TARBP2 expression vector (pLPC-TARBP2 wt) was constructed by cloning the cDNA corresponding to the wild-type gene TARBP2 into a pLPC vector. The truncated form of TRBP was constructed by cloning the cDNA corresponding to TARBP2 truncated from Co115 into a pCMV-Tag4B vector, pCMV-Tag4B-TARBP2-Mut. The DICER1 expression vector pCMV-Tag4B-DICER1 was constructed by cloning the cDNA corresponding to the gene DICER1 into a pCMV-Tag4B vector. Transfection of Co115 cells was done by electroporating 10 7 cells in 0.8 ml PBS with 40 mg of the vector at 250 V and 975 mF. After electroporation, cells were washed with PBS and seeded in fresh medium. Clones expressing wild-type TRBP were selected in complete medium supplemented with 0.5 mg ml -1 puromycin; clones expressing the truncated form of TRBP were selected in complete medium supplemented with 1 mg ml -1 G418; clones expressing DICER1 were selected in complete medium supplemented with 1 mg ml -1 G418 and clones coexpressing TRBP wild-type and DICER1 were selected in complete medium supplemented with 0.5 mg ml À1 puromycin and 1 mg ml À1 G418.
Transfection of miRs precursor molecules. miR-19a, miR-138, miR-30a, miR148a, miR-12b1, miR-125b2 and miR let7a precursor molecules and negative control miRNAs were purchased from Ambion. We carried out experiments involving transient transfections of pre-miRNAs with oligofectamine (Invitrogen) using 100 nmol/l RNA duplexes. The cells were collected 48 h and 72 h after transfection, and the expression of precursor and mature miRNAs was assessed by qRT-PCR, as described above.
miRNA expression study by microarray. Briefly, 5 mg of RNA from each tissue sample was labeled with biotin by reverse transcription using random octomers. Hybridization was carried out on the second version of a miRNA-chip 18 , which contained 238 probes for mature miRNAs. Each oligo was printed in duplicate in two different slide locations. Hybridization signals were detected by biotin binding of a Streptavidin-Alexa647 conjugate (one-color signal) using a GenePix 4000B scanner (Axon Instruments). We quantified images using the GenePix Pro 6.0 (Axon Instruments). Raw data were analyzed in Corrigendum: A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function In the version of this article initially published, the colony formation assay image labeled "Co115.DICER1" was the incorrect image. The error has been corrected and a corrected version of Figure 4 panel e is provided in the HTML and PDF versions of the article.
